Lucentis

Lucentis (Ranibizumab) is an intravitreal injection used to treat eye conditions. This medication is designed to address specific retinal disorders, offering targeted therapy for improved vision outcomes.

Lucentis is primarily used for the treatment of wet age-related macular degeneration (AMD), a condition that can lead to vision loss. It is also used to manage certain types of diabetic retinopathy and macular edema, which can cause swelling and damage to the retina. The medication works by inhibiting vascular endothelial growth factor (VEGF), which can help reduce abnormal blood vessel growth in the eye.

Common effects of Lucentis may include temporary eye discomfort, redness, or increased floaters. Some patients may experience vision disturbances immediately after the injection. These effects are generally mild and resolve on their own. Serious side effects are rare but can include severe eye inflammation or infection.

Lucentis should only be administered by a healthcare professional experienced in intravitreal injections. Patients should inform their doctor about any eye infections or inflammation before treatment. Regular eye exams are recommended to monitor for any potential complications.

Lucentis may interact with other medications, particularly those that affect the immune system or blood vessels. Patients should discuss all current medications with their healthcare provider before starting treatment. Alcohol and certain supplements may also influence the effectiveness of Lucentis.